Report cover image

Immuno-Oncology - Thematic Research

Publisher GlobalData
Published May 30, 2022
Length 167 Pages
SKU # GBDT17311314

Description

Immuno-Oncology - Thematic Research

Summary

The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer

Checkpoint modulation is the most valuable IO sector

Within 2021-2022, the next immuno-oncology breakthrough has not happened

High cost of therapy and need for personalized treatment using biomarkers remain as unmet needs

Scope
  • Overview of immuno-oncology including classification of therapy and technologies, regulatory and market access details, product & company profiles.
  • Quotes from US- and 5EU-based key opinion leaders and payers.
  • Key topics covered for IO in the 8MM include trends, value chain, market analysis, opportunities, challenges and unmet needs and high-value deals.
  • Pipeline analysis: Comprehensive data split across different phases and indications, emerging novel trends under development, and analysis of the most promising late-stage pipeline drugs for each class of IO (Phase II - III).
  • Analysis of the key dynamics of the IO market. Insightful review of the key industry drivers and challenges. Deals and R&D strategies covered in detail to highlight business opportunities.
  • Robust analysis of high-prescriber survey conducted with 80 oncologists.
Reasons to Buy
  • What impact will late-stage pipeline agents have on the market? Which class of IO drugs will have the highest peak sales, and why?
  • What are the current unmet needs in IO, which pipeline agents or strategies are positioned to counter these unmet needs? What are the opportunities for R&D?
  • How is the field of checkpoint modulation going to move forward? Which technologies are the most promising for combinations?
  • What is the regulatory landscape for IO agents in the US, the 5EU Japan, and China?
  • What is the current and future outlook of IO according to high prescribers?

Table of Contents

167 Pages
  • Executive Summary
    • What is Immuno-oncology
    • What is Immuno-oncology According To Regulators
    • What is Immuno-oncology
    • Most Important Milestones of Immuno-oncology Development Globally
    • Key Twitter Chat
    • Industry Trends - Bispecific Antibodies
    • Industry Trends - Cancer Vaccines
    • Industry Trends - Cell Therapies
    • Industry Trends - Checkpoint Modulators
    • Industry Trends - Cytokines
    • Industry Trends - Oncolytic Viruses
    • Regulatory Trends
    • Immuno-oncology Value Chain
    • Bispecific Antibodies
    • Bispecific Antibodies - KOL Perspective
    • Cancer Vaccines
    • Cancer Vaccines - KOL Perspective
    • Cell Therapies
    • Cell Therapies - KOLs Perspective
    • Checkpoint Modulators
    • Checkpoint Modulators - KOL Perspective
    • Next-generation Cytokines
    • Cytokines - KOL Perspective
    • Oncolytic Viruses
    • Oncolytic Viruses - KOL Perspective
    • Immuno-oncology in Clinical Trials
    • Ten new immune checkpoint inhibitors were approved in just over one year, most in China
    • Total Market Size for Immuno-oncology Agents
    • 10 Highest-Grossing Immuno-oncology Treatments in 2021
    • Leading Checkpoint Modulators in the 8MM
    • Checkpoint Modulator Treatments - KOL Perspective
    • Leading Checkpoint Modulators in the 8MM
    • Checkpoint Modulator Treatments - KOL Perspective
    • Leading Cancer Vaccines, Bispecific Antibodies, and Oncolytic Viruses in the 8MM
    • Bispecific Antibody, Cancer Vaccine, or Oncolytic Virus Treatments - KOL Perspective
    • Leading Cell Therapies in the 8MM
    • Cell Therapy Treatments - KOL Perspective
    • Leading Cell Therapies in the 8MM
    • Immuno-oncology Pipeline Products in the 8MM
    • Future Outlook of IO Agents, According to High-Prescribing Physicians
    • Consensus Forecast Sales for the Top Three Pipeline Candidates per IO Class
    • The Forecast Highest-Grossing Bispecific Antibody Products
    • Bispecific Antibody Treatments - KOL Perspective
    • The Forecast Highest-Grossing Vaccine Products
    • Cancer Vaccine Treatments - KOL Perspective
    • The Forecast Highest-Grossing Cell Therapy Products
    • Cell Therapy Treatments - KOL Perspective
    • The Forecast Highest-Grossing Checkpoint Modulator Products
    • Checkpoint Modulator Treatments - KOL Perspective
    • The Forecast Highest-Grossing Cytokine Products
    • Cytokines - KOL Perspective
    • The Forecast Highest-Grossing Oncolytic Virus Products
    • Oncolytic Virus Treatments - KOLs Perspective
    • Market Analysis and Forecast of the Six Classes of IO Agents
    • Top 10 Strategic Partnership Deals of the Last Decade by Size in the IO Space
    • Latest Strategic Partnership Deals in the IO Space
    • Mergers and Acquisitions that Include IO Assets: 2020-2021
    • Mergers and Acquisitions that Include IO Assets: 2016-2020
    • Immuno-oncology in Clinical Trials
    • Clinical Trials
    • Differences in Immuno-oncology Clinical Trials - KOL Perspective
    • Challenges in Immuno-oncology Clinical Trials - KOL Perspective
    • Regulatory and Market Access - US
    • Key Market Access and Regulatory Concepts - US
    • Market Access - US Payer & KOL Perspective
    • Regulatory and Market Access - EU
    • Key Market Access and Regulatory Concepts - Europe
    • Market Access - EU Payer & KOL Perspective
    • Regulatory and Market Access - Japan
    • Market Access - Japan KOL Perspective
    • Key Market Access and Regulatory Concepts - Japan
    • Regulatory and Market Access - China
    • Market Access - China KOL Perspective
    • Key Market Access and Regulatory Concepts - China
    • Early Access Schemes
    • Barriers to Access According to High Prescribers
    • Bispecific Antibodies
    • Cancer Vaccines
    • Cancer Vaccines - Additional KOL Perspective
    • Cell Therapies
    • Cell Therapies - Additional KOL Perspective
    • Checkpoint Modulators
    • Checkpoint Modulators - Additional KOL Perspective
    • Cytokines
    • Oncolytic Viruses
    • Clinical Unmet Needs in Immuno-oncology - Gap Analysis
    • Commercial Unmet Needs in Immuno-oncology - Gap Analysis
    • Unmet Needs - KOL Perspective
    • Unmet Needs According to High Prescribers
    • R&D Strategies
    • Opportunities for the Industry - Modern Approaches & Collaboration
    • Closing Remarks - In Their Words
    • Drug Development Scorecard - Immuno-oncology
    • Current Major Players - Novartis
    • Current Major Players - Merck & Co.
    • Current Major Players - Gilead Sciences
    • Current Major Players - Roche
    • Current Major Players - BMS
    • Current Major Players - AstraZeneca
    • Current Major Players - Sanofi
    • Current Major Players - Amgen
    • Current Major Players - Dendreon Pharmaceuticals
    • Current Major Players - Legend Biotech
    • Current Major Players - Johnson & Johnson
    • Future Players Based on Pipeline Strength - Alphamab
    • Future Players Based on Pipeline Strength - Genmab
    • Future Players Based on Pipeline Strength - Regeneron
    • Future Players Based on Pipeline Strength - Iovance Therapeutics
    • Future Players Based on Pipeline Strength - Replimune
    • Future Players Based on Pipeline Strength - Oncolytics
    • Future Players Based on Pipeline Strength - Inovio
    • Future Players Based on Pipeline Strength - VBI Vaccines
    • Future Players Based on Pipeline Strength - Instil Bio
    • Future Players Based on Pipeline Strength - Alaunos Therapeutics
    • Future Players Based on Pipeline Strength - Jounce Therapeutics
    • Future Players Based on Pipeline Strength - Arcus Biosciences
    • Future Players Based on Pipeline Strength - Neoleukin Therapeutics
    • Future Players Based on Pipeline Strength - Alkermes
    • Future Players Based on Pipeline Strength - Oncosec
    • Future Players Based on Pipeline Strength - Oncorus
    • Sources
    • Primary Research
    • Key Themes Impacting the Pharmaceutical Industry
    • Our thematic research methodology

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us